RxDoctor Payments Data

Leah Webb

Nurse Practitioner · Albany, GANPI 1689945644

Payments from drug & device makers

$2,845in general payments, 2019–2025

Across 126 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$773
  • AbbVie$636
  • Biocryst US Sales Co., LLC$338
  • Lilly USA, LLC$219
  • Dexcom, Inc.$107
  • Boehringer Ingelheim$76
  • plus $697 from 23 others

What the payments were for

  • Food & beverage$2,845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,845 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$25,049
Medicare patients
155
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$91,102
RybelsusSemaglutide21$43,669
TrulicityDulaglutide28$33,707
MounjaroTirzepatide29$30,851
EliquisApixaban25$22,808
JardianceEmpagliflozin12$10,865
JanuviaSitagliptin Phosphate13$6,693
MyrbetriqMirabegron11$6,488
Albuterol Sulfate HfaAlbuterol Sulfate93$1,846
Gabapentin72$1,320
Atorvastatin Calcium134$962
Levocetirizine Dihydrochloride91$849
Levothyroxine Sodium84$798
Losartan Potassium95$782
Duloxetine Hcl48$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$773$134,770117 claims
Lilly USA, LLCTrulicity, Mounjaro$219$64,55757 claims
PfizerEliquis$35$22,80825 claims
Boehringer IngelheimJardiance$76$10,86512 claims
MerckJanuvia$19$6,69313 claims
Astellas Pharma US IncMyrbetriq$33$6,48811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →